Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

An Evaluation of the Potential for VH4011499 Drug-drug-interactions

9. November 2026 aktualisiert von: ViiV Healthcare

A Phase 1, Open-label Study to Evaluate the Potential for VH4011499 Drug-drug-interactions in HIV Negative Adult Participants

The purpose of this study is to evaluate the pharmacokinetic (PK) interactions between VH4011499 and representative drugs containing inhibitors and inducers, selected transporters, and statins, in HIV negative adults. The study will also assess to assess safety and tolerability during co-administration of VH4011499 with the selected drugs.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Geschätzt)

75

Phase

  • Phase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 60 Jahre (Erwachsene)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Participants must be 18 to 60 years of age inclusive at the time of signing the informed consent form (ICF).

  • Male or female:

    1. Male Participants:

      No restrictions for male participants.

    2. A female participant (female sex assigned at birth) is eligible to participate if:

They are a woman of non-child bearing potential (WONCBP). There is no requirement for female study participants to use a highly effective method of contraception since, to be eligible, they must be of nonchildbearing potential.

  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, vital signs, cardiac monitoring, and clinical laboratory evaluations at Screening.
  • Body weight ≥50.0 kg (110 lbs) for men and ≥45.0 kg (99 lbs) for women and body mass index within the range 18.5 to 32.0 kg/m^2 (inclusive).
  • Capable of giving signed informed consent.

Exclusion Criteria:

  • History or presence of clinical condition or disorder that could be capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study drugs, interfering with the interpretation of data or would make the participant unsuitable for the study; unable to comply with dosing requirements; or unable to comply with study visits.
  • Pre-existing clinically relevant, gastro-intestinal pathology or diagnosis.
  • A history, or current abnormality in glucose metabolism requiring concomitant use of insulin or other medications for glucose control.
  • Clinically significant abnormal blood pressure at Screening.
  • Lymphoma, leukemia, or any malignancy within the past 5 years (with specified exceptions) or breast cancer within the past 10 years.
  • Breast cancer within the past 10 years.
  • Current or chronic history of liver disease or known hepatic or biliary abnormalities, or history of hepatic porphyria.
  • History of syncope, clinically significant palpitations, cardiac arrhythmias or other cardiac diseases or a family and personal history of long QT syndrome.
  • History of seizure(s) and / or other clinically significant neurological conditions.
  • Pre-existing psychiatric condition, that would pose a safety risk to the participant or interfere with participation in the study.
  • Participants with any history of any drug hypersensitivity, delayed-type hypersensitivity, or severe hypersensitivity reactions, as well as history of sensitivity to the study interventions.
  • Participant is mentally or legally incapacitated.
  • Cohort 3: VH4011499 + Carbamazepine ONLY: Participants who are carriers of the HLA-B*15:02 and/or HLA-A*31:01 gene.
  • Cohort 3: VH4011499 + Carbamazepine ONLY: History of bone marrow depression, aplastic anemia, agranulocytosis, or other clinically significant hematologic or bone marrow disorder.
  • Unable to refrain from the use of prescription or non-prescription medications.
  • Use of monoamine oxidase inhibitors (MAOIs) within 14 days prior to Day -1.
  • Cohort 3:VH4011499 + Carbamazepine ONLY: Known hypersensitivity to carbamazepine, oxcarbazepine, or tricyclic compounds.
  • Exposure to more than 4 new investigational products within 12 months prior to the first dosing day.
  • Current enrollment or past participation in another investigational study in which an investigational intervention, within the protocol-defined exclusion period.
  • Participant has donated or lost blood, or has donated plasma within 30 days prior to first administration.
  • Current enrollment or past participation in this clinical study.
  • Unwillingness or inability to follow the procedures outlined in the protocol.
  • eGFR <90 mL/min or serum creatinine >1.1× upper limit of normal (ULN) .
  • Hemoglobin <12.5 g/dL for men and <11 g/dL for women.
  • Participants with active hepatitis B virus (HBV) based on any of the following are excluded: 1) Positive hepatitis B surface antigen (HBsAg), 2) Positive hepatitis B surface antibody (HBcAb) except HBV DNA is negative.
  • Positive Hepatitis C antibody test result at Screening.
  • Positive pre-study drug/alcohol screen.
  • Positive HIV-1 antibody / antigen fourth generation test (point of care test or laboratory immunoassay) and / or acute viral symptoms with no alternative etiology within 3 weeks prior to Screening.
  • Cohort 3: VH4011499 + Carbamazepine ONLY: Clinically significant hematologic abnormalities at Screening.
  • Cohort 3: VH4011499 + Carbamazepine ONLY: Serum sodium <135 millimole/L.
  • Regular alcohol consumption within 6 months prior to Screening.
  • Regular use of known drugs of abuse.
  • Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to Screening and at admission.
  • Sensitivity to the study drugs, or components thereof, or other drug or other allergy that, contraindicates participation in the study.
  • Prior exposure to VH4011499 or Lenacapavir in any formulation..
  • Study participants with ALT >1.0x ULN or total bilirubin >1.5x ULN are excluded at Screening.
  • Any significant arrhythmia or ECG findings meeting protocol-defined exclusion criteria.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Grundlegende Wissenschaft
  • Zuteilung: Nicht randomisiert
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Cohort 1: VH4011499 + Ritonavir

Participants receive a single dose of VH4011499 at Day 1, followed by a 21-day washout period. On days 23-54, participants receive Ritonavir twice daily. On Day 26, participants receive another single dose of VH4011499, along with Ritonavir.

VH4011499 is administered to the participants based on the protocol schedule.

Ritonavir is administered to the participants based on the protocol schedule.

Experimental: Cohort 2: VH4011499 + Efavirenz

Participants receive a single dose of VH4011499 at Day 1, followed by a 21-day washout period. On days 23-58, participants receive Efavirenz once daily. On Day 37, participants receive another single dose of VH4011499, along with Efavirenz.

VH4011499 is administered to the participants based on the protocol schedule.

Efavirenz is administered to the participants based on the protocol schedule.

Experimental: Cohort 3: VH4011499 + Carbamazepine

Participants receive a single dose of VH4011499 at Day 1, followed by a 21-day washout period. On days 23-25, participants receive Carbamazepine low dose; on days 26-28, they receive Carbamazepine medium dose; and on days 29-62, they receive Carbamazepine high dose. On Day 41, the participants receive another single dose of VH4011499, along with Carbamazepine high dose.

VH4011499 is administered to the participants based on the protocol schedule.

Carbamazepine is administered to the participants based on the protocol schedule.

Experimental: Cohort 4: VH4011499 + Metformin + Digoxin

Participants receive a dose of Metformin and Digoxin on Day 1, followed by a 14-day washout period. On days 10-24, participants receive VH4011499 once daily (a higher dose on Day 10, followed by a lower dose on days 11-24). On Day 16, participants receive another dose of Metformin and Digoxin, along with VH4011499.

VH4011499 is administered to the participants based on the protocol schedule.

Metformin is administered to the participants based on the protocol schedule.

Digoxin is administered to the participants based on the protocol schedule.

Experimental: Cohort 5: VH4011499 + Rosuvastatin + Pitavastatin

Participants receive a dose of Rosuvastatin on Day 1, and a dose of Pitavastatin on Day 5, followed by a 10-day washout period. On days 11-26, participants receive VH4011499 once daily (a higher dose on Day 11, followed by a lower dose on days 12-26). On Day 17, participants receive another dose of Pitavastatin, and on Day 22 they receive another dose of Rosuvastatin, along with VH4011499.

VH4011499 is administered to the participants based on the protocol schedule.

Rosuvastatin is administered to the participants based on the protocol schedule.

Pitavastatin is administered to the participants based on the protocol schedule.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Zeitfenster
Maximum plasma concentration (Cmax) of VH4011499 when administered alone
Zeitfenster: Day 1 for Cohorts 1, 2 and 3
Day 1 for Cohorts 1, 2 and 3
Cmax of VH4011499 when co-administered with Ritonavir
Zeitfenster: Day 26
Day 26
Cmax of VH4011499 when co-administered with Efavirenz
Zeitfenster: Day 37
Day 37
Cmax of VH4011499 when co-administered with Carbamazepine
Zeitfenster: Day 41
Day 41
Area under the concentration-time curve from 0 to tau [AUC(0-t)] of VH4011499 when administered alone
Zeitfenster: Day 1 for Cohorts 1, 2 and 3
Day 1 for Cohorts 1, 2 and 3
AUC(0-t) of VH4011499 when co-administered with Ritonavir
Zeitfenster: Day 26
Day 26
AUC(0-t) of VH4011499 when co-administered with Efavirenz
Zeitfenster: Day 37
Day 37
AUC(0-t) of VH4011499 when co-administered with Carbamazepine
Zeitfenster: Day 41
Day 41
Area under the concentration-time curve from 0 to infinity [AUC(0-inf)] of VH4011499 when administered alone
Zeitfenster: Day 1 for Cohorts 1, 2 and 3
Day 1 for Cohorts 1, 2 and 3
AUC(0-inf) of VH4011499 when co-administered with Ritonavir
Zeitfenster: Day 26
Day 26
AUC(0-inf) of VH4011499 when co-administered with Efavirenz
Zeitfenster: Day 37
Day 37
AUC(0-inf) of VH4011499 when co-administered with Carbamazepine
Zeitfenster: Day 41
Day 41
Cmax of Metformin when administered alone
Zeitfenster: Day 1
Day 1
Cmax of Metformin when co-administered with VH4011499
Zeitfenster: Day 16
Day 16
AUC(0-t) of Metformin when administered alone
Zeitfenster: Day 1
Day 1
AUC(0-t) of Metformin when co-administered with VH4011499
Zeitfenster: Day 16
Day 16
AUC(0-inf) of Metformin when administered alone
Zeitfenster: Day 1
Day 1
AUC(0-inf) of Metformin when co-administered with VH4011499
Zeitfenster: Day 16
Day 16
Cmax of Digoxin when administered alone
Zeitfenster: Day 1
Day 1
Cmax of Digoxin when co-administered with VH4011499
Zeitfenster: Day 16
Day 16
AUC(0-t) of Digoxin when administered alone
Zeitfenster: Day 1
Day 1
AUC(0-t) of Digoxin when co-administered with VH4011499
Zeitfenster: Day 16
Day 16
AUC(0-inf) of Digoxin when administered alone
Zeitfenster: Day 1
Day 1
AUC(0-inf) of Digoxin when co-administered with VH4011499
Zeitfenster: Day 16
Day 16
Cmax of Rosuvastatin when administered alone
Zeitfenster: Day 5
Day 5
Cmax of Rosuvastatin when co-administered with VH4011499
Zeitfenster: Day 22
Day 22
AUC(0-t) of Rosuvastatin when administered alone
Zeitfenster: Day 5
Day 5
AUC(0-t) of Rosuvastatin when co-administered with VH4011499
Zeitfenster: Day 22
Day 22
AUC(0-inf) of Rosuvastatin when administered alone
Zeitfenster: Day 5
Day 5
AUC(0-inf) of Rosuvastatin when co-administered with VH4011499
Zeitfenster: Day 22
Day 22
Cmax of Pitavastatin when administered alone
Zeitfenster: Day 1
Day 1
Cmax of Pitavastatin when co-administered with VH4011499
Zeitfenster: Day 17
Day 17
AUC(0-t) of Pitavastatin when administered alone
Zeitfenster: Day 1
Day 1
AUC(0-t) of Pitavastatin when co-administered with VH4011499
Zeitfenster: Day 17
Day 17
AUC(0-inf) of Pitavastatin when administered alone
Zeitfenster: Day 1
Day 1
AUC(0-inf) of Pitavastatin when co-administered with VH4011499
Zeitfenster: Day 17
Day 17

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Number of participants with adverse events (AEs), overall and by grade.
Zeitfenster: Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. The intensity of AEs is reported based on the Division of acquired immunodeficiency syndrome (DAIDS) grading scale, where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=potentially life-threatening, Grade 5=death.

Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
Number of participants with AEs leading to study treatment discontinuation
Zeitfenster: Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
Number of participants with change from baseline in alanine transaminase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), direct bilirubin and total bilirubin
Zeitfenster: Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
Number of participants with maximum toxicity grade increase in alanine transaminase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), direct bilirubin and total bilirubin
Zeitfenster: Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.

The toxicity is reported based on DAIDS grading scale, where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=potentially life-threatening, Grade 5=death.

Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
Time to maximum plasma concentration (Tmax) of VH4011499 when administered alone.
Zeitfenster: Day 1 for Cohorts 1, 2 and 3
Day 1 for Cohorts 1, 2 and 3
Tmax of VH4011499 when co-administered with Ritonavir
Zeitfenster: Day 26
Day 26
Tmax of VH4011499 when co-administered with Efavirenz
Zeitfenster: Day 37
Day 37
Tmax of VH4011499 when co-administered with Carbamazepine
Zeitfenster: Day 41
Day 41
Apparent oral clearance (CL/F) of VH4011499 when administered alone
Zeitfenster: Day 1 for Cohorts 1, 2 and 3
Day 1 for Cohorts 1, 2 and 3
CL/F of VH4011499 when co-administered with Ritonavir
Zeitfenster: Day 26
Day 26
CL/F of VH4011499 when co-administered with Efavirenz
Zeitfenster: Day 37
Day 37
CL/F of VH4011499 when co-administered with Carbamazepine
Zeitfenster: Day 41
Day 41
Apparent terminal half-life (t1/2) of VH4011499 when administered alone
Zeitfenster: Day 1 for Cohorts 1, 2 and 3
Day 1 for Cohorts 1, 2 and 3
t1/2 of VH4011499 when co-administered with Ritonavir
Zeitfenster: Day 26
Day 26
t1/2 of VH4011499 when co-administered with Efavirenz
Zeitfenster: Day 37
Day 37
t1/2 of VH4011499 when co-administered with Carbamazepine
Zeitfenster: Day 41
Day 41
Cmax of VH4011499 when co-administered with Metformin and Digoxin
Zeitfenster: Day 16
Day 16
AUC(0-t) of VH4011499 when co-administered with Metformin and Digoxin
Zeitfenster: Day 16
Day 16
AUC(0-inf) of VH4011499 when co-administered with Metformin and Digoxin
Zeitfenster: Day 16
Day 16
Cmax of Ritonavir when co-administered with VH4011499
Zeitfenster: Day 26
Day 26
AUC(0-t) of Ritonavir when co-administered with VH4011499
Zeitfenster: Day 26
Day 26
AUC(0-inf) of Ritonavir when co-administered with VH4011499
Zeitfenster: Day 26
Day 26
Cmax of Efavirenz when co-administered with VH4011499
Zeitfenster: Day 37
Day 37
AUC(0-t) of Efavirenz when co-administered with VH4011499
Zeitfenster: Day 37
Day 37
AUC(0-inf) of Efavirenz when co-administered with VH4011499
Zeitfenster: Day 37
Day 37
Cmax of Carbamazepine when co-administered with VH4011499
Zeitfenster: Day 41
Day 41
AUC(0-t) of Carbamazepine when co-administered with VH4011499
Zeitfenster: Day 41
Day 41
AUC(0-inf) of Carbamazepine when co-administered with VH4011499
Zeitfenster: Day 41
Day 41
Cmax of VH4011499 when co-administered with Rosuvastatin
Zeitfenster: Day 22
Day 22
AUC(0-t) of VH4011499 when co-administered with Rosuvastatin
Zeitfenster: Day 22
Day 22
AUC(0-inf) of VH4011499 when co-administered with Rosuvastatin
Zeitfenster: Day 22
Day 22
Cmax of VH4011499 when co-administered with Pitavastatin
Zeitfenster: Day 17
Day 17
AUC(0-t) of VH4011499 when co-administered with Pitavastatin
Zeitfenster: Day 17
Day 17
AUC(0-inf) of VH4011499 when co-administered with Pitavastatin
Zeitfenster: Day 17
Day 17

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

16. November 2026

Primärer Abschluss (Geschätzt)

12. März 2027

Studienabschluss (Geschätzt)

12. März 2027

Studienanmeldedaten

Zuerst eingereicht

9. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

9. November 2026

Zuerst gepostet (Tatsächlich)

16. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

16. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

9. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 309014

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_28May2026.pdf

IPD-Sharing-Zeitrahmen

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

IPD-Sharing-Zugriffskriterien

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT
  • ICF
  • CSR

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .